(Q40134051)

17 September 2017

title

Bortezomib significantly impairs the immunostimulatory capacity of human myeloid blood dendritic cells (English)

1 reference

17 September 2017

1 reference

4

Bornhäuser M

1 reference

17 September 2017

Straube C

1

1 reference

17 September 2017

Wehner R

2

1 reference

17 September 2017

Wendisch M

3

1 reference

17 September 2017

Bachmann M

5

1 reference

17 September 2017

Rieber EP

6

1 reference

17 September 2017

Schmitz M

7

1 reference

17 September 2017

publication date

10 May 2007

1 reference

17 September 2017

1 reference

17 September 2017

volume

21

1 reference

17 September 2017

issue

7

1 reference

17 September 2017

page(s)

1464-1471

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.leu.2404734

17 September 2017

exact match

0 references

cites work

The proteasome: a suitable antineoplastic target

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404734

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404734

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404734

Proteasome inhibitor bortezomib for the treatment of multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404734

Bortezomib: proteasome inhibition as an effective anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404734

Proteasome inhibitors: antitumor effects and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404734

United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404734

Proteasome inhibition as a novel therapeutic target in human cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404734

NF-kappa B as a therapeutic target in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404734

Dendritic cells and the control of immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404734

Immunobiology of dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404734

Antigen presentation and T cell stimulation by dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404734

Dendritic cells as therapeutic vaccines against cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404734

Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404734

Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404734

Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404734

Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404734

Select forms of tumor cell apoptosis induce dendritic cell maturation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404734

Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, Velcade).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404734

Proteasome inhibitor-induced apoptosis in human monocyte-derived dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404734

Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404734

Proteasomal chymotrypsin-like peptidase activity is required for essential functions of human monocyte-derived dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404734

6-Sulfo LacNAc, a novel carbohydrate modification of PSGL-1, defines an inflammatory type of human dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404734

Tumoricidal potential of native blood dendritic cells: direct tumor cell killing and activation of NK cell-mediated cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404734

Approval summary for bortezomib for injection in the treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404734

CD83 on dendritic cells: more than just a marker for maturation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404734

Interleukin-12 and the regulation of innate resistance and adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404734

CD4 T cells and their role in antitumor immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404734

The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404734

Primary antitumor immune response mediated by CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404734

Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404734

Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404734

Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404734

Potential therapeutic role of natural killer cells in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404734

Surface NK receptors and their ligands on tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404734

Enhancement of human cord blood CD34+ cell-derived NK cell cytotoxicity by dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404734

Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404734

Anti-myeloma activity of natural killer lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404734

HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404734

The dialogue between human natural killer cells and dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404734

7 January 2021

Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404734

7 January 2021

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404734

7 January 2021

A novel dendritic cell population in human blood: one-step immunomagnetic isolation by a specific mAb (M-DC8) and in vitro priming of cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404734

7 January 2021

Human 6-sulfo LacNAc-expressing dendritic cells are principal producers of early interleukin-12 and are controlled by erythrocytes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404734

7 January 2021

Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404734

7 January 2021

The role of CD4+ T cell responses in antitumor immunity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404734

7 January 2021

Imatinib mesylate does not impair the immunogenicity of human myeloid blood dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404734

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2404734

1 reference

Dimensions Publication ID

17 September 2017

1018498353

0 references

1 reference